---
schema_version: "secwatch.filing_event.v1"
accession: "0001641172-25-005241"
form_type: "8-K"
ticker: "HEPA"
cik: "0001583771"
company_name: "Hepion Pharmaceuticals, Inc."
filed_at: "2025-04-17T23:59:59+00:00"
generated_at: "2026-05-23T11:53:09.786309+00:00"
event_type: "regulatory"
sentiment: "negative"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Nasdaq deems Hepion a 'public shell' as additional delisting basis; hearing April 29

## Summary
- Received Nasdaq notice on April 15, 2025, alleging company is a 'public shell' and continued listing unwarranted.
- Nasdaq Hearings Panel will consider this matter at hearing scheduled for April 29, 2025.
- Company intends to present its views on the additional deficiency at the Panel hearing.

## SEC filing metadata
- accession: 0001641172-25-005241
- form_type: 8-K
- ticker: HEPA
- cik: 0001583771
- company_name: Hepion Pharmaceuticals, Inc.
- filed_at: 2025-04-17T23:59:59+00:00
- event_type: regulatory
- sentiment: negative
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 3.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1583771/000164117225005241/0001641172-25-005241-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1583771/000164117225005241/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001641172-25-005241
- JSON: https://secwatch.observer/filing/0001641172-25-005241.json
- Plain text: https://secwatch.observer/filing/0001641172-25-005241.txt

## Key facts
- Listing & Compliance Notices
  Hepion Pharmaceuticals, Inc. received a nasdaq delisting notice notice regarding other.
  - Exchange: nasdaq
  - Notice: delisting notice
  source text: April 15, 2025, Hepion Pharmaceuticals, Inc., a Delaware corporation (the “ Company ”), received written notice (the “ Notice ”) from the Nasdaq Stock Market, LLC (“ Nasdaq ”) indicating that the Staff believes that the Company is a “public shell” and that the continued listing of its securities is no longer warranted. The Staff stated that this serves as an additional basis for delisting the Company’s securities from The Nasdaq Stock Market. The Notice is formal notification that the Nasdaq Hearings Panel (the “Panel”) will consider this matter in rendering a determination regarding the Compa
  evidence_url: https://www.sec.gov/Archives/edgar/data/1583771/000164117225005241/0001641172-25-005241-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.